Topoisomerase poisoning activity of novel disaccharide anthracyclines

Molecular Pharmacology

Volumn 56, Issue 1, 1999, Pages 77-84

  Guano, Fulvio ^a   Pourquier, Philippe ^b   Tinelli, Stella ^a   Binaschi, Monica ^a   Bigioni, Mario ^c   Animati, Fabio ^c   Manzini, Stefano ^c   Zunino, Franco ^a   Kohlhagen, Glenda ^b   Pommier, Yves ^b   Capranico, Giovanni ^a,d  

^a Istituto Nazionale per lo Studio   (Italy)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Menarini Ricerche SpA   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; IDARUBICIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DNA CLEAVAGE; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; NONHUMAN; PRIORITY JOURNAL; SACCHAROMYCES CEREVISIAE;

EID: 0033064653     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.56.1.77     Document Type: Article

References (42)

1. Arcamone F (1981) Doxorubicin, in Anticancer Antibiotics pp 1-369, Academic Press, New York.
2. Arcamone F, Animati F, Berettoni M, Bigioni M, Capranico G, Casazza AM, Caserini C, Cipollone A, De Cesare M, Franciotti M, et al (1997a) A doxorubicin disaccharide analog: Apoptosis-related improvement of efficacy in vivo. J Natl Cancer Inst 89:1217-1223.
3. Arcamone F, Animati F, Bigioni M, Capranico G, Caserini C, Cipollone A, De Cesare M, Ettorre A, Guano F, Manzini S, Monteagudo E, Pratesi G, Salvatore C, Supino R and Zunino F (1999) Configurational requirements of the sugar moiety for the pharmacological activity of anthracycline disaccharides. Biochem Pharmacol 57: 1133-1139.
4. Arcamone F, Animati F, Capranico G, Lombardi P, Pratesi G, Supino R and Zunino F (1997b) New developments in antitumor anthracyclines. Pharmacol Ther 76: 117-124.
5. Austin CA, Marsh KL, Wasserman RA, Willmore E, Sayer PJ, Wang JC and Fisher LM (1995) Expression, domain structure, and enzymatic properties of an active recombinant human DNA topoisomerase II beta. J Biol Chem 270:15739-15746.
6. Baldari C, Murray JAH, Ghiara P, Cesareni G and Galeotti CL (1987) A novel leader peptide which allows efficient secretion of a fragment of human interleukin 1β in Saccharomyces cerevisiae. EMBO J 6:229-234.
7. Binaschi M, Farinosi R, Austin CA, Fisher LM, Zunino F and Capranico G (1998) Human DNA topoisomerase IIalpha-dependent DNA cleavage and yeast cell killing by anthracycline analogues. Cancer Res 58:1886-1892.
8. Bjornsti MA, Benedetti P, Viglianti GA and Wang JC (1989) Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: Restoration of sensitivity of the cells to the antitumor drug camptothecin. Cancer Res 49:6318-6323.
9. Capranico G, Binaschi M, Borgnetto ME, Zunino F and Palumbo M (1997) A protein-mediated mechanism for the DNA sequence-specific action of topoisomerase II poisons. Trends Pharmacol Sci 18:303-346.
10. Capranico G, Butelli E and Zunino F (1995) Change of the sequence specificity of daunorubicin-stimulated topoisomerase II DNA cleavage by epimerization of the amino group of the sugar moiety. Cancer Res 55:312-317.
11. Capranico G, Guano F, Moro S, Zagotto G, Sissi C, Gatto B, Zunino F, Menta E and Palumbo M (1998) Mapping drug interactions at the covalent topoisomerase II-DNA complex by Bisantrene/Amsacrine congeners. J Biol Chem 273:12732-12739.
12. Capranico G, Palumbo M, Tinelli S, Mabilia M, Pozzan A and Zunino F (1994a) Conformational drug determinants of the sequence specificity of drug-stimulated topoisomerase II DNA cleavage. J Mol Biol 235:1218-1230.
13. Capranico G, Supino R, Binaschi M, Capolongo L, Grandi M, Suarato A and Zunino F (1994b) Influence of structural modifications at the 3′ and 4′ positions of doxorubicin on the drug ability to trap topoisomerase II and to overcome multidrug resistance. Mol Pharmacol 45:908-915.
14. Capranico G, Zunino F, Kohn KW and Pommier Y (1990) Sequence-selective topoisomerase II inhibition by anthracycline derivatives in SV40 DNA: Relationship with DNA binding affinity and cytotoxicity. Biochemistry 29:562-569.
15. Cornarotti M, Tinelli S, Willmore E, Zunino F, Fisher LM, Austin CA and Capranico G (1996) Drug sensitivity and sequence specificity of human recombinant DNA topoisomerase IIα (p170) and IIβ (p180). Mol Pharmacol 50:1463-1471.
16. De Isabella P, Capranico G, Binaschi M, Tinelli S and Zunino F (1990) Evidence of DNA topoisomerase II-dependent mechanisms of multidrug resistance in P388 leukemia cells. Mol Pharmacol 37:11-16.
17. Fan Y, Weinstein JN, Kohn KW, Shi LM and Pommier Y (1998) Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin. J Med Chem 41:2216-2226.
18. Freudenreich CH and Kreuzer KN (1994) Localization of an aminoacridine antitumor agent in a type II topoisomerase-DNA complex. Proc Natl Acad Sci USA 91:11007-11011.
19. Froelich-Ammon SJ and Osheroff N (1995) Topoisomerase poisons: Harnessing the dark side of enzyme mechanism. J Biol Chem 270:21429-21432.
20. Gupta M, Fujimori A and Pommier Y (1995) Eukaryotic DNA topoisomerase I. Biochim Biophys Acta 1262:1-14.
21. Hertzberg RP, Busby RW, Caranfa MJ, Holden KG, Johnson RK, Hecht SM and Kingsbury WD (1990) Irreversible trapping of the DNA-topoisomerase I covalent complex. Affinity labeling of the camptothecin binding site. J Biol Chem 265: 19287-19295.
22. Hertzberg RP, Caranfa MJ and Hecht SM (1989) On the mechanism of topoisomerase I inhibition by camptothecin: Evidence for binding to an enzyme-DNA complex. Biochemistry 28:4629-4638.
23. Jaxel C, Capranico G, Kerrigan D, Kohn KW and Pommier Y (1991) Effect of local DNA sequence on topoisomerase I cleavage in the presence or absence of camptothecin. J Biol Chem 266:20418-20423.
24. Leteurtre F, Fujimori A, Tanizawa A, Chhabra A, Mazumder A, Kohlhagen G, Nakano H and Pommier Y (1994) Saintopin, a dual inhibitor of DNA topoisomerases I and II, as a probe for drug-enzyme interactions. J Biol Chem 269:28702-28707.
25. Makhey D, Gatto B, Yu C, Liu A, Liu LF and LaVoie EJ (1996) Coralyne and related compounds as mammalian topoisomerase I and topoisomerase II poisons. Bioorg Med Chem 4:781-791.
26. Meczes EL, Marsh KL, Fisher LM, Rogers MP and Austin CA (1997) Complementation of temperature-sensitive topoisomerase II mutations in Saccharomyces cerevisiae by a human TOP2 beta construct allows the study of topoisomerase II beta inhibitors in yeast. Cancer Chemother Pharmacol 39:367-375.
27. Nabiev I, Chourpa I, Riou JF, Nguyen CH, Lavelle F and Manfait M (1994) Molecular interactions of DNA-topoisomerase I and II inhibitor with DNA and topoisomerases and in ternary complexes: Binding modes and biological effects for intoplicine derivatives. Biochemistry 33:9013-9023.
28. Nitiss J and Wang JC (1988) DNA topoisomerase-targeting antitumor drugs can be studied in yeast. Proc Natl Acad Sci USA 85:7501-7505.
29. Nitiss JL (1994) Using yeast to study resistance to topoisomerase II-targeting drugs. Cancer Chemother Pharmacol 34(Suppl):S6-S13.
30. Nitiss JL, Liu YX, Harbury P, Jannatipour M, Wasserman R and Wang JC (1992) Amsacrine and etoposide hypersensitivity of yeast cells overexpressing DNA topoisomerase II. Cancer Res 52:4467-4472.
31. Nitiss JL, Liu YX and Hsiung Y (1993) A temperature sensitive topoisomerase II allele confers temperature dependent drug resistance on amsacrine and etoposide: A genetic system for determining the targets of topoisomerase II inhibitors. Cancer Res 53:89-93.
32. Nitiss JL, Pourquier P and Pommier Y (1997) Aclacinomycin A stabilizes topoisomerase I covalent complex. Cancer Res 57:4564-4569.
33. Nitiss JL, Zhou J, Rose A, Hsiung Y, Gale KC and Osheroff N (1998) The bis(naphthalimide) DMP-840 causes cytotoxicity by its action against eukaryotic topoisomerase II. Biochemistry 37:3078-3085.
34. Poddevin B, Riou J-F, Lavelle F and Pommier Y (1993) Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials. Mol Pharmacol 44:767-774.
35. Pommier Y, Kohlhagen G, Kohn KW, Leteurtre F, Wani MC and Wall ME (1995) Interaction of an alkylating camptothecin derivative with a DNA base at topoisomerase I-DNA cleavage sites. Proc Natl Acad Sci USA 92:8861-8865.
36. Pourquier P, Pilon AA, Kohlhagen G, Mazumder A, Sharma A and Pommier Y (1997) Trapping of mammalian topoisomerase I and recombinations induced by damaged DNA containing nicks or gaps. Importance of DNA end phosphorylation and camptothecin effects. J Biol Chem 272:26441-26447.
37. Redinbo MR, Stewart L, Kuhn P, Champoux JJ and Hol WG (1998) Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. Science (Wash DC) 279:1504-1513.
38. Shen LL, Kohlbrenner WE, Weigl D and Baranowski J (1989) Mechanism of quinolone inhibition of DNA gyrase. Appearance of unique norfloxacin binding sites in enzyme-DNA complexes. J Biol Chem 264:2973-2978.
39. Sim SP, Gatto B, Yu C, Liu AA, Li TK, Pilch DS, LaVoie EJ and Liu LF (1997) Differential poisoning of topoisomerases by menogaril and nogalamycin dictated by the minor groove-binding nogalose sugar. Biochemistry 36:13285-13291.
40. Trask DK and Muller MT (1988) Stabilization of type I topoisomerase-DNA covalent complexes by actinomycin D. Proc Natl Acad Sci USA 85:1417-1421.
41. Wassermann K, Markovits J, Janel C, Capranico G, Kohn KW and Pommier Y (1990) Effects of morpholinyl doxorubicins, doxorubicin, and actinomycin D on mammalian DNA topoisomerases I and II. Mol Pharmacol 38:38-45.
42. Wasserman RA, Austin CA, Fisher LM and Wang JC (1993) Use of yeast in the study of anticancer drugs targeting DNA topoisomerases: Expression of a functional recombinant human DNA topoisomerase IIa in yeast. Cancer Res 53:3591-3596.